Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Roche Holding (SWX:ROG) has been on investors’ radar after recent share price swings, with the stock showing mixed returns over the past week, month, and past 3 months.
See our latest analysis for Roche Holding.
At around CHF322.3 per share, Roche Holding’s recent 1-month share price return of a 10.47% decline contrasts with a positive 1-year total shareholder return of 10.30%. This suggests shorter term momentum has cooled while longer term returns remain positive.
If recent healthcare volatility has you reassessing where to put fresh capital, it could be worth widening your search to other potential growth stories in medical technology and diagnostics through 122 healthcare AI stocks
With Roche trading around CHF322.3 and an indicated intrinsic discount of 63.17%, plus a value score of 5, the key question is whether the recent pullback leaves genuine upside on the table or if the market is already pricing in future growth.
According to the most followed narrative, Roche Holding’s fair value of CHF430 sits well above the recent CHF322.3 share price, creating a clear valuation gap that hinges on the strength of its pipeline and cash flow profile.
The most significant catalyst is the company’s pipeline, which is poised to deliver a new wave of blockbuster drugs: • CT-388 (Obesity): This drug has the potential to be a multi-billion dollar product. Phase II trials showed an impressive 22.5% placebo-adjusted weight loss, positioning it as a strong competitor to market leaders from Novo Nordisk and Eli Lilly. Phase III trials are commencing in Q1 2026, representing a major near-term milestone.
Curious how a single obesity candidate, a packed late stage pipeline, and firm profit margins combine into that CHF430 figure? The key ingredients are specific earnings, cash flow, and valuation assumptions that paint a very different picture to the current share price.
Result: Fair Value of CHF430 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this thesis still hinges on successful late stage trial results and timely approvals, while competitive pressure in obesity and oncology could quickly challenge the CHF430 fair value story.
Find out about the key risks to this Roche Holding narrative.
With sentiment clearly split between risks and rewards, it makes sense to move quickly and test the story against the numbers yourself. You can start with 5 key rewards and 1 important warning sign.
Do not stop with one company when there are entire lists of stocks already filtered for quality, value, and resilience that you can review in minutes.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com